AUPH
Aurinia Pharmaceuticals Inc.NASDAQHealthcare$15.61+0.90%ClosedMarket Cap: $2.08B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
7.23
PEG
0.00
P/B
3.70
P/S
7.52
EV/EBITDA
14.91
DCF Value
$-48.01
FCF Yield
6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.5%
Operating Margin
37.1%
Net Margin
101.5%
ROE
70.4%
ROA
38.2%
ROIC
15.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $77.1M | $210.8M | $1.53 |
| FY 2025 | $283.1M | $287.2M | $2.07 |
| Q3 2025 | $73.5M | $31.6M | $0.23 |
| Q2 2025 | $70.0M | $21.5M | $0.15 |
Analyst Ratings
View AllLeerink PartnersMarket Perform
2025-12-03JefferiesBuy
2025-11-07RBC CapitalSector Perform
2025-11-05RBC CapitalOutperform
2025-08-01Trading Activity
Insider Trades
View AllCole Ryanofficer
SellThu Apr 02
Hearne Michael Sofficer
SellThu Apr 02
Keenan Gregofficer: SVP, Chief Medical Officer
SellTue Mar 10
TANG KEVINdirector
BuyTue Mar 03
TANG KEVINdirector
BuyTue Mar 03
Company Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
1.52
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.